Oncology Clinical Trials Design and Management

Oncology Clinical Trials Design & Management

Medelis is a full service oncology clinical research company, focused on the oncology clinical trials design and management for phase I and II studies in North America and Europe.

Our world-class medical advisory board, medical founders and team physicians are internationally-recognized oncology thought leaders. Our team knows when new agents are coming into clinical development, and we work with our clients to create the best strategy to move treatments through the clinic.

Our team has the experience, tools and processes to streamline the design and management of complex oncology clinical trials.

We’ve handled most targets within oncology. Whether it’s a standard dose-escalation phase I trial or a complex rescue of a phase III trial, chances are that our team has handled it before.

Full Service Oncology Clinical Research

— view full service list

Efficient Clinical Trial Planning and Execution

Our clinical team’s comprehension of the complex issues of oncology trials translates into better problem identification, decision making and superior results. We value innovation, and our experience allows us to work smarter, to maximize cost and time efficiencies on your trial.

  • A highly-skilled oncology clinical team
  • Streamlined trial planning and execution
  • Flexibility to create time and cost efficiencies
  • Fastest trial startup in the industry
  • World class oncology advisory board
  • A proactive partner you can trust

A True Partner Managing Your Trial

We’re flexible, collaborative and proactive, and able to quickly adapt to study challenges or changes in the regulatory or competitive environment. This helps to speed a drug to market, and provides the decision support to determine your next clinical move.

Contact us to start a discussion about your upcoming study.

Tell Us About Your Study

We’d love to hear from you, and can provide feedback about your study design, investigators and patient recruitment, indications, and data collection.